GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Phase 3

Recruiting

Conditions: Lung Diseases, Interstitial

Interventions: Biological: Belimumab
Other: Placebo

First Posted Date: 2024-08-27

Last Posted Date: 2025-04-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 440

Registration Number: NCT06572384

Locations: 🇬🇧
GSK Investigational Site, Leicester, United Kingdom

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Phase 2

Recruiting

Conditions: Neoplasms, Colon

Interventions: Biological: Dostarlimab
Drug: CAPEOX

First Posted Date: 2024-08-23

Last Posted Date: 2025-03-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 120

Registration Number: NCT06567782

Locations: 🇧🇪
GSK Investigational Site, Leuven, Belgium

A Study of GSK5764227 in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Biological: GSK5764227
Drug: Cisplatin
Drug: Carboplatin
Biological: Atezolizumab
Biological: Pembrolizumab
Biological: Durvalumab
Biological: Cetuximab
Biological: Bevacizumab

First Posted Date: 2024-08-13

Last Posted Date: 2025-03-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 281

Registration Number: NCT06551142

Locations: 🇬🇧
GSK Investigational Site, Edinburgh, United Kingdom

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

Phase 3

Recruiting

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA investigational vaccine
Drug: Placebo

First Posted Date: 2024-08-13

Last Posted Date: 2024-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2600

Registration Number: NCT06551181

Locations: 🇬🇧
GSK Investigational Site, Witney, United Kingdom

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Phase 2

Recruiting

Conditions: Chronic Hepatitis B Virus Infection
Hepatitis B

Interventions: Drug: Daplusiran/Tomligisiran Dose Level 1
Drug: Daplusiran/Tomligisiran Dose Level 2
Drug: Placebo
Drug: Bepirovirsen

First Posted Date: 2024-08-05

Last Posted Date: 2025-05-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 280

Registration Number: NCT06537414

Locations: 🇬🇧
GSK Investigational Site, Middlesbrough, United Kingdom

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Phase 3

Recruiting

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSVPreF3 OA vaccine

First Posted Date: 2024-08-02

Last Posted Date: 2025-04-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15500

Registration Number: NCT06534892

Locations: 🇬🇧
GSK Investigational Site, Witney, United Kingdom

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

Recruiting

Conditions: Lupus Nephritis

Interventions: Other: None (Observational study)

First Posted Date: 2024-07-30

Last Posted Date: 2024-11-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 300

Registration Number: NCT06527872

Locations: 🇺🇸
GSK Investigational Site, Charlotte, North Carolina, United States

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1

Recruiting

Conditions: Ependymoma
Osteosarcoma
Melanoma
Hodgkin Lymphoma
High and Low Grade Glioma
Glioblastoma Multiforme (GBM)
Diffuse Intrinsic Pontine Glioma (DIPG)
Hepatic Tumors
Hepatocellular Carcinoma (HCC)
Hepatoblastoma

Interventions: Drug: Cobolimab
Drug: Dostarlimab

First Posted Date: 2024-07-26

Last Posted Date: 2025-05-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 95

Registration Number: NCT06521567

Locations: 🇪🇸
GSK Investigational Site, Valencia, Spain

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Phase 1

Recruiting

Conditions: Primary Myelofibrosis
Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis